Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[QuiPO: who inject EPO?].

Cécile Vigneau1, Sylvie Le Stum2, Corinne Isnard-Bagnis3

  • 1Service de néphrologie, CHU Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex, France; Université Rennes 1, 2, rue Léon-Bernard, 35000 Rennes, France.

Nephrologie & Therapeutique
|December 3, 2014
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors for acquisition of SARS-CoV-2 Omicron variant among a prospective cohort of French Healthcare Workers: impact of hybrid immunity.

Scientific reports·2026
Same author

Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.

Journal of medical economics·2026
Same author

Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.

EClinicalMedicine·2026
Same author

Left Ventricular Function and Atrial Remodeling Shape Outcomes After Mitral-Transcatheter Edge-to-Edge Repair.

ESC heart failure·2026
Same author

The epidemiology of end-stage kidney failure in France: reason for hope?

Clinical kidney journal·2026
Same author

Chronic kidney disease stage 4 and 5: comparison of therapeutic projects before kidney replacement therapy between men and women in Brittany.

Journal of nephrology·2026
This summary is machine-generated.

Despite advancements in Erythropoiesis Stimulating Agents (ESA) for chronic kidney disease patients, self-administration remains low. Most patients rely on nurses, increasing costs and hindering independence.

Area of Science:

  • Nephrology
  • Pharmacology
  • Patient Self-Management

Background:

  • Erythropoiesis Stimulating Agents (ESA) are crucial for chronic kidney disease (CKD) patients predialysis.
  • Despite pharmaceutical efforts to enhance self-administration (e.g., advanced devices, monthly injections), patient uptake is unclear.

Purpose of the Study:

  • To determine the percentage of CKD patients who self-administer ESAs.
  • To compare the costs associated with self-administration versus nurse-administered injections.

Main Methods:

  • A prospective questionnaire study was conducted across French nephrology departments.
  • 143 pre-dialysis CKD patients treated with ESAs completed questionnaires.
  • Costs were evaluated based on ESA and nurse visit expenses, analyzed using a Wilcoxon test.
Keywords:
ASEAuto-injectionsESAInfirmièreNursePatient

Related Experiment Videos

Main Results:

  • Only 24.8% of patients self-administer ESAs; 70.2% utilize nurses.
  • Self-administration is significantly higher among working patients (56.8% vs. 34.7%).
  • Nurse administration is more costly than self-injection (P=0.0016).

Conclusions:

  • A minority of CKD patients self-administer ESAs, despite improved administration methods.
  • Reliance on nurses for ESA injections does not promote patient independence and elevates healthcare costs.
  • Further efforts are needed to improve ESA self-administration rates among CKD patients.